Italian biotech NanoPhoria Bioscience closed Italy’s largest-ever Series A financing in biotech, raising €83.5 million ($97.6 million) to advance NP-MP1, a novel peptide therapy targeting heart failure with reduced ejection fraction (HFrEF). The therapy enhances cardiac contractility by modulating L-type calcium channels and has demonstrated efficacy in preclinical large animal models. CEO Claudio De Luca emphasized a strategic focus on life sciences investors and robust preclinical data in securing funding. This financing will accelerate clinical development and pipeline expansion, aiming to address a major unmet need in cardiac care.